NCT07220603 is a Phase 2 clinical trial of PGN-EDODM1 in Myotonic Dystrophy 1, sponsored by PepGen Inc.

Who is sponsoring NCT07220603?

NCT07220603 is sponsored by PepGen Inc.

What drugs are being tested in NCT07220603?

Interventions in NCT07220603: PGN-EDODM1.

What condition does NCT07220603 study?

NCT07220603 studies Myotonic Dystrophy 1.

Is NCT07220603 still recruiting?

NCT07220603 is currently recruiting now. Last updated 26 March 2026.

Last reviewed 2026-03-26 · How we verify

NCT07220603

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Open-Label Extension Study Evaluating Safety and Pharmacokinetics in Participants With Myotonic Dystrophy Type 1 (FREEDOM-OLE)

Recruiting now Phase 2 Last updated 26 March 2026

What this trial tests

Phase 2 trial testing PGN-EDODM1 in Myotonic Dystrophy 1 in 48 participants. Currently enrolling.

Timeline

23 December 2025

Primary endpoint
1 January 2029

1 January 2029

Quick facts

Lead sponsor	PepGen Inc
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	48
Start date	23 December 2025
Primary completion	1 January 2029
Estimated completion	1 January 2029
Sites	3 locations across Canada

Drugs / interventions tested

PGN-EDODM1 — full drug profile →

Conditions studied

Myotonic Dystrophy 1 — all drugs for Myotonic Dystrophy 1 →

Sponsor

PepGen Inc — full company profile →

Who can join

Eligibility, any sex, with Myotonic Dystrophy 1. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Safety and tolerability as assessed by number of participants with Adverse Events (AEs)
Time frame: Baseline through Week 108

Sponsor's own description

The purpose of this study is to learn about the long-term safety and tolerability of PGN-EDODM1 in participants with myotonic dystrophy type 1 (DM1) who have completed a prior study with PGN-EDODM1.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Myotonic Dystrophy 1

Currently open trials in the same condition.

NCT07385443 — The Spanish National Registry for Myotonic Dystrophy Type 1 · recruiting
NCT06378216 — Myotonic Dystrophy Type 1 Congenital and Juvenile Form: From Diagnosis to Rehabilitation [MDCJ-NeuBeRe] · recruiting
NCT03981575 — Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) · recruiting

Other PepGen Inc trials

Trials by the same sponsor.

NCT06833931 — A Study of PGN-EDO51 or Placebo in People With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment · Phase 2 · withdrawn
NCT06079736 — A Study Of PGN-EDO51 In Participants With Duchenne Muscular Dystrophy Amenable To Exon 51-Skipping Treatment · Phase 2 · terminated
NCT06204809 — Safety, Tolerability, PK, and PD Study of PGN-EDODM1 in Participants With Myotonic Dystrophy Type 1 · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07220603 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by PepGen Inc
Last refreshed: 26 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07220603.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing